Congress asks for recall of flea collar that may be linked to nearly 1,700 pet deaths

Elanco claims request is ‘based on recent misleading media coverage’

James Crump
Friday 19 March 2021 18:35

EPA Documents Link Seresto Flea Collars To Pet Deaths, Injuries

Leer en Español

A Congressional subcommittee has asked that a popular flea and tick collar be recalled after being linked to the deaths of close to 1,700 pets.

Democratic representative Raja Krishnamoorthi, of Illinois, who serves as chairman of the subcommittee on Economic and Consumer Policy, sent pharmaceutical company Elanco a letter on Thursday asking it to recall its Seresto collar.

The subcommittee asked the company to also release information about the toxicity of its product and to issue full refunds to customers affected.

The collar works by releasing tiny amounts of pesticide onto the animal over several months, which is supposed to kill fleas and ticks that are harmful to pets including cats and dogs.

However, since it was first sold in 2012, the US Environmental Protection Agency (EPA) has received more than 75,000 reports about humans and pets being harmed by the collar.

The reports include 1,678 pet deaths and 907 injuries to humans, but the subcommittee believes the actual number is much greater.

Read more:

Mr Krishnamoorthi wrote that the members of Congress believe this “since the average consumer would not know to report pet harm to EPA, an agency seemingly unrelated to consumer pet products.”

Although the Seresto brand is owned by Elanco, it was developed by pharmaceutical company Bayer, before it was sold to the latter business in 2020 for $7.5bn (£5.3bn). The Independent has contacted Elanco for comment.

In a statement to The Independent on Friday, Bayer said: “Bayer completed its sale of its animal health division to Elanco in August of 2020 and this sale included Seresto flea and tick products. We no longer manufacture or market this product.”

In a statement on Thursday, Elanco said that the subcommittee’s request is “based on recent misleading media coverage” and denied that its collars are responsible for widespread harm.

The company claimed that “the incident report rate … in the US has been below 0.3 per cent” and said that “a report is not an indication of cause.”

Senior director for Technical Consultants at Elanco, Dr Tony Rumschlag, added: “There is no medical or scientific basis to initiate a recall of Seresto collars and we are disappointed this is causing confusion and unfounded fear for pet owners trying to protect their pets from fleas and ticks.”

While in a statement to The Independent, an Elanco official said: “Seresto remains available to consumers as an effective way to protect their pets against fleas and ticks, that can transmit disease and can impact their quality of life.

“All data and scientific evaluation used during the product registration process and through Elanco’s robust pharmacovigilance review supports the product’s safety profile and efficacy. Therefore, no market action, such as a recall, is warranted, nor has it been suggested from any regulatory agency.”

However, Mr Krishnamoorthi wrote in the letter to Elanco that the subcommittee believes it is better to be cautious, saying: “I think that it’s only appropriate in this case that the manufacturer do a voluntary recall.”

He added: “We look at the situation, investigate and then proceed from there.”

Elanco confirmed to CBS News that it is cooperating with the subcommittee but said it would only issue a recall if asked by regulators.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies


Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in